8-K: Kyverna Advances Autoimmune CAR T, Reports Q4/FY25 Results

Kyverna Therapeutics reported strong clinical progress for its autoimmune CAR T programs, including a planned BLA submission for stiff person syndrome in 1H 2026, and extended its cash runway into 2028.

Summary

• Reported business highlights and financial results for the fourth quarter and full year ended December 31, 2025.
• Advancing first-to-market autoimmune CAR T opportunity in stiff person syndrome (SPS) with Biologics License Application (BLA) submission anticipated in the first half of 2026.
• Progressing enrollment for FDA-aligned Phase 3 trial in generalized myasthenia gravis (gMG).
• Positive progressive multiple sclerosis (PMS) data underscore valuable pipeline-in-a-product opportunity with miv-cel.
• Cash and cash equivalents of $279.3 million as of December 31, 2025, providing expected runway into 2028.
• Net loss for the fourth quarter 2025 was $37.8 million, and for the full year 2025 was $161.3 million.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive update given the strong clinical trial results and clear path to BLA submission for SPS, despite increased net losses which are typical for a late-stage biopharmaceutical company in development.

Positives

• Miv-cel achieved highly statistically significant clinical benefit across all primary and secondary endpoints in the KYSA-8 trial for stiff person syndrome (SPS), including reversing disability.
• Miv-cel was generally well-tolerated in SPS and gMG trials, with no high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) observed, supporting the potential for outpatient administration.
• Positive interim data from the Phase 2 portion of the KYSA-6 clinical trial for generalized myasthenia gravis (gMG) achieved all primary and secondary endpoints, demonstrating miv-cel's potential for durable, drug-free, disease-free remission after a single dose.
• Positive updated Phase 1 data from investigator-initiated trials (IITs) evaluating miv-cel in progressive multiple sclerosis (PMS) showed 83% (5/6) of patients achieved improvements in disability scores, with all (4/4) showing improvements in fatigue scores.
• Positive data from the Phase 1 portion of a Phase 1/2 IIT evaluating miv-cel in treatment-refractory rheumatoid arthritis (RA) demonstrated profound reduction in disease-associated autoantibodies and impact on disease activity.
• The investigational new drug (IND) application was accepted by the FDA for KYV-102, the company's proprietary whole blood, rapid manufacturing process.
• Current manufacturing capacity is expected to fully support commercial launch for SPS.
• Strengthened the balance sheet and extended cash runway into 2028 through a combination of financing activities, raising a total of $147.5 million.
• Expanded the company's expertise through key Board of Directors and leadership appointments, including Christi Shaw as Executive Chairperson of the Board, and Sravan K. Emany, Andrew Miller to the Board, and Mayo Pujols as Chief Technology Officer.

Negatives

• Net loss for the full year ended December 31, 2025, increased to $161.3 million, compared to $127.5 million for the full year 2024.
• Research and Development (R&D) expenses increased to $133.7 million for the full year 2025, from $112.5 million for the full year 2024.
• General and Administrative (G&A) expenses increased to $36.1 million for the full year 2025, from $30.1 million for the full year 2024.
• Cash and cash equivalents decreased from $285.979 million as of December 31, 2024, to $279.253 million as of December 31, 2025, despite recent capital raises.

Risks

• Uncertainties related to market conditions.
• The possibility that results from prior clinical trials, named-patient access activities, and preclinical studies may not necessarily be predictive of future results.
• The possibility that the FDA or other regulatory agencies may require additional trials or studies to support its intended BLA submission.
• Intellectual property rights issues.
• Other factors discussed in the Risk Factors section of Kyverna's Annual Report on Form 10-K for the year ended December 31, 2025, to be filed with the U.S. Securities and Exchange Commission.

Future Outlook

Kyverna anticipates submitting its first Biologics License Application (BLA) for miv-cel in stiff person syndrome in the first half of 2026 and expects to be launch-ready by year-end 2026. The company is progressing its FDA-aligned Phase 3 gMG clinical trial and plans to report additional data for PMS, RA, and Lupus Nephritis in 2026, along with sharing the development strategy for KYV-102. The current cash runway is expected to fund operations into 2028, covering the SPS BLA filing, commercial launch, and Phase 3 gMG trial.

Management Comments

• "We continue to cement our leadership in autoimmune CAR T supported by our unique construct and a growing body of transformative clinical data that reinforces miv-cel's differentiated profile." Warner Biddle, Chief Executive Officer of Kyverna Therapeutics.
• "We are advancing the first CAR T for stiff person syndrome, a serious and debilitating disease with no FDA-approved treatments, representing a significant unmet need and meaningful commercial opportunity." Warner Biddle, Chief Executive Officer of Kyverna Therapeutics.
• "Our market entry will establish the foundation for our neuroimmunology franchise with expansion into generalized myasthenia gravis and potentially other indications, such as progressive multiple sclerosis, where miv-cel has shown promising clinical benefit." Warner Biddle, Chief Executive Officer of Kyverna Therapeutics.

Industry Context

StockSavvy.ai notes that Kyverna Therapeutics is positioning itself as a leader in the emerging field of CAR T-cell therapy for autoimmune diseases, a significant pivot from its traditional oncology applications. The focus on stiff person syndrome (SPS), a rare disease with no FDA-approved treatments, could provide a first-mover advantage and establish a strong neuroimmunology franchise before expanding into larger indications like generalized myasthenia gravis and progressive multiple sclerosis, where competition is growing but unmet needs remain high.

Comparison to Industry Standards

• Miv-cel's safety profile, with no high-grade CRS or ICANS observed in SPS and gMG trials, compares favorably to some early-generation CAR T therapies in oncology which often presented with more severe adverse events, potentially enabling outpatient administration.
• The achievement of highly statistically significant clinical benefit across all primary and secondary endpoints in SPS is a strong indicator of efficacy, potentially setting a high bar for future treatments in this rare disease space.
• The durable, drug-free, disease-free remission potential in gMG after a single dose, if confirmed in Phase 3, would represent a significant advancement over existing chronic immunosuppressive therapies.

Management Changes

Stakeholder Impact

• Shareholders: Potential for significant value creation if miv-cel successfully launches for SPS and expands into other indications, supported by extended cash runway. Increased net losses and R&D/G&A expenses reflect ongoing investment in pipeline.
• Patients (SPS): High positive impact due to potential first FDA-approved treatment for a serious and debilitating disease, offering significant clinical benefit including disability reversal.
• Patients (gMG, PMS, RA, Lupus Nephritis): Positive outlook with ongoing clinical trials showing promising results, potentially leading to new treatment options.
• Employees: Growth and expansion indicated by leadership hires and advancement of multiple clinical programs.
• Creditors: Strengthened balance sheet with new loan facility and extended cash runway provides greater security.

Next Steps

• Report primary analysis of registrational KYSA-8 trial for SPS at AAN in April 2026.
• BLA filing for SPS in 1H 2026.
• Launch-ready for SPS by year-end 2026.
• Report updated data for the Phase 2 portion of KYSA-6 trial for gMG at AAN in April 2026.
• Report additional data from Phase 1 IIT in Progressive Multiple Sclerosis in 2026.
• Report Phase 2 IIT data for Rheumatoid Arthritis in 2026.
• Report Phase 1 data for Lupus Nephritis in 2026.
• Share development strategy for KYV-102, Kyverna's whole blood rapid manufacturing process.

Key Dates

Recommendation

The filing details highly significant positive clinical trial results for miv-cel in stiff person syndrome, with a clear path to BLA submission in 1H 2026 and commercial launch readiness by year-end 2026. This represents a first-to-market opportunity in a disease with no approved treatments. Additionally, promising data in generalized myasthenia gravis and progressive multiple sclerosis, coupled with an extended cash runway into 2028, significantly de-risk the company's pipeline and future growth prospects, making it a compelling investment. While net losses increased, this is expected for a company advancing multiple late-stage clinical assets.

Keywords

Kyverna Therapeutics, KYTX, CAR T-cell therapy, autoimmune diseases, stiff person syndrome, generalized myasthenia gravis, progressive multiple sclerosis, rheumatoid arthritis, miv-cel, KYV-101, Biologics License Application, BLA, clinical trials, financial results, biopharmaceutical, neuroimmunology, cell therapy